Abstract
We have used human erythroleukemia (HEL) cells to investigate distal signaling mechanisms of neuropeptide-Y (NPY) receptors. NPY did not activate phospholipase D, determined as a phosphatidylethanol formation, or protein kinase C (PKC) determined enzymatically as a translocation to the plasma membrane. However, NPY caused a rapid (already maximal after 30 s) and concentration-dependent (maximum at 10–100 nM) activation of extracellular signal-regulated kinase (ERK) as assessed by immunoblotting with epitope-specific, antiphosphotyrosine antibodies and in some cases enzymatically. ERK activation by 100 nM NPY was abolished by the Y1 NPY receptor antagonist BIBP 3226 (1 μM), pertussis toxin treatment (100 ng ml−1 overnight), the mitogen-activated protein kinase (MAPK) kinase inhibitor PD 98059 (100 μM), and the phosphatidylinositol-3-kinase inhibitor wortmannin (100 nM). Whereas the PKC inhibitor staurosporine (3 μM) inhibited ERK activation by NPY, the chemically distinct PKC inhibitors calphostin C (3 μM), Gö 6976 (3 μM), and bisindolylmaleimide I (3 μM) did not. NPY did not activate other MAPK such as jun N-terminal kinase or p38 MAPK. We conclude that NPY does not activate phospholipase D, PKC, jun N-terminal kinase, or p38 MAPK in HEL cells. However, NPY activates ERK by a pathway involving Y1 receptors, pertussis toxin-sensitive G proteins, and phosphatidylinositol-3-kinase, whereas PKC may not be involved. Staurosporine may have PKC-independent effects on ERK activation.
Footnotes
-
Send reprint requests to: Dr. Martin C. Michel, Nephrologisches Labor IG 1, Klinikum, 45122 Essen, Germany. E-mail: martin.michel{at}uni-essen.de
-
↵1 This work was supported in part by a grant from the Deutsche Forschungsgemeinschaft (Mi 294/5-2).
- Abbreviations:
- NPY
- neuropeptide-Y
- CHO
- Chinese hamster ovary
- ERK
- extracellular signal-regulated kinase
- HEL
- human erythroleukemia
- JNK
- Jun N-terminal kinase
- MAPK
- mitogen-activated protein kinase
- PKC
- protein kinase C
- PMA
- phorbol-12-myristate-13-acetate
- MEK
- mitogen-activated protein/extracellular signal-related kinase kinase
- Received March 3, 1999.
- Accepted August 18, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|